baber/WOPTO huggingface dataset:
Patent JP-3283262-B2 (JP)
IPC: H01L29/78
Filed: 1993-06-07
Granted: 2002-05-20
Abstract: A silicon carbide power MOSFET device includes a first silicon carbide layer, epitaxially formed on the silicon carbide substrate of opposite conductivity type. A second silicon carbide layer of the same conductivity type as the substrate is formed on the first silicon carbide layer. A power field effect transistor is formed in the device region of the substrate and in the first and second silicon carbide layers thereover. At least one termination trench is formed in the termination region of the silicon carbide substrate, extending through the first and second silicon carbide layers thereover. The termination trench defines one or more isolated mesas in the termination region which act as floating field rings. The termination trenches are preferably insulator lined and filled with conductive material to form floating field plates. The outermost trench may be a deep trench which extends through the first and second silicon carbide layers and through the drift region of the silicon carbide substrate. Since the termination region is formed from the first and second silicon carbide layers in the termination region, a time consuming, high temperature diffusion to form a floating field ring is not necessary. Rather, the same epitaxial first and second silicon carbide layers which are used to form an FET in the device region may also be used to form the floating field ring in the termination region.
Patent JP-3315112-B2 (JP)
IPC: C07F5/00
Filed: 1990-03-06
Granted: 2002-08-19
Abstract: The present invention involves a novel tripyrrole dimethine-derived "expanded porphyrin" (texaphyrin), the synthesis of such compounds, their analogs or derivatives and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Metal complexes of these compounds are active as photosensitizers for the generation of singlet oxygen and thus potentially for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus and tumor cells as well. A variety of texaphyrin derivatives have been produced and many more are readily obtainable. Various metal (e.g., transition, main group, and lanthanide) complexes with the texaphyrin and texaphyrin derivatives of the present invention have unusual water solubility and stability which render them particularly useful. These metallotexaphyrin complexes have optical properties making them unique as compared to existing porphyrin-like or other macrocycles. For example, they absorb light strongly in a physiologically important region (i.e. 690-880 nm). These complexes also form long-lived triplet states in high yield and act as efficient photosensitizers for the formation of singlet oxygen. These properties, coupled with their high chemical stability and appreciable solubility in polar media such as water, add to their usefulness.
Patent JP-2706247-B2 (JP)
IPC: C12N1/20
Filed: 1987-10-21
Granted: 1998-01-28
Abstract: An expression vector capable of expressing, in a transformed host, a protein which is capable of being detected by ELISA with anti-human apoAI antiserum and which has the formula (1) Met-X-Y      (1) wherein X is a b                                               ond, a carrier peptide sequence which comprises a sequence derived from the N-terminal amino acid residues of beta-galactosidase or a sequence comprising one or more IgG-binding domains of Protein A, or the pro sequence of human apoAI; and Y represents the sequence of human apoAI or a genetic variant thereof. Hosts transformed with such vectors produce the protein, which is useful in the treatment of atherosclerosis and cardiovascular diseases.
Patent JP-3571344-B2 (JP)
IPC: C23F11/18
Filed: 1994-09-08
Granted: 2004-09-29
Abstract: A nonaqueous engine coolant utilizes propylene glycol and propylene glycol-soluble corrosion-inhibiting additives which do not require water to enter into or remain in solution thereby reducing toxicity levels and corrosiveness exhibited by aqueous coolants.
Patent JP-3621427-B2 (JP)
IPC: A61K31/404
Filed: 1998-07-17
Granted: 2005-02-16
Abstract: Agent for treatment or prevention of glomerulopathy comprise a sulphonamide derivative of formula R4-R3-SO2-N(R2)C(R1)COY (I) or its salt or hydrate. R1, R2 = H or optionally substituted lower alkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl; R3 = 4-phenylene or 2,5-thiophendiyl; R4 = OPh, Tet-Ph, Ctriple boundCPh, NHCOPh, Het-Ph, phenyl parasubstituted by R6 or 2-R5-thiophen-5-ylethynyl; Ph = phenyl para-substituted by R6; Tet = tetrazol-2,5-diyl; Het = oxazol-2,5-diyl or oxadiazol-3,5-diyl bonded to phenyl through the 5 and 3 positions respectively or thiophen-2,5-diyl; R5 = H, OH, lower alkylthio, SH, cycloalkyl, halo, COOH, lower alkoxycarbonyl, NO2, CN, lower haloalkyl, aryloxy, guanidino, lower alkenyl, lower alkynyl, acyl, acyloxy, CONRaRb, NRcCORd or optionally substituted lower alkoxy, amino, lower alkyl, unsaturated heterocyclyl or heteroaryl; Ra-Rc = H, lower alkyl or aralkyl; Rd = lower alkyl, aryl or aralkyl; R6 = cycloalkyl, lower alkoxy, halo, lower alkylthio, carboxy, lower alkoxycarbonyl, aryloxy, phenyl or optionally substituted lower alkyl, amino, unsaturated heterocyclyl or heteroaryl; Y = NHOH or OH. (I) are new when R4 = 2-R5-thiophen-5-ylethynyl, Ph-Tet or Ph-Het1 and R3 = 2,5-thiophen-diyl; or R4 = Ph-Het2 and R3 = 4-phenylene; Het1 = oxazol-2,5-diyl; Het2 = 2,5-thiophendiyl, tetrazol-2,5-diyl bonded to Ph through the 5 position or oxadiazol-3,5-yl; R5, R6 = H, lower alkylthio, halo or optionally substituted alkoxy, amino, alkyl or unsaturated heterocyclyl and R2 = H or lower alkyl.
Patent JP-3031707-B2 (JP)
IPC: G02F1/29
Filed: 1991-05-06
Granted: 2000-04-10
Abstract: A light activated switching device is disclosed in which the receipt of a light signal is used to switch a light beam between two output ports. The input light beam is reflected from an interface between two regions having different indices of refraction when the light signal is present. The reflected light beam then exits through the first output port. In the absence of the light signal, the two regions have the same index of refraction, and the light beam passes through both regions and exits through the second output port.
Patent JP-4176146-B2 (JP)
IPC: C12Q1/689
Filed: 1995-09-12
Granted: 2008-11-05
Abstract: The present invention relates to DNA-based methods for universal bacterial detection, for specific detection of the pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epiderminis, Enterococcus faecalis, Staphylococcus saprophyticus, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis as well as for specific detection of commonly encountered and clinically relevant bacterial antibiotic resistance genes directly from clinical specimens or, alternatively, from a bacterial colony. The above bacterial species can account for as much as 80% of bacterial pathogens isolated in routine microbiology laboratories. The core of this invention consists primarily of the DNA sequences from all species-specific genomic DNA fragments selected by hybridization from genomic libraries or, alternatively, selected from data banks as well as any oligonucleotide sequences derived from these sequences which can be used as probes or amplification primers for PCR or any other nucleic acid amplification methods. This invention also includes DNA sequences from the selected clinically relevant antibiotic resistance genes.
Patent JP-2916265-B2 (JP)
IPC: G01R27/06
Filed: 1993-12-29
Granted: 1999-07-05
Abstract: PCT No. PCT/FI93/00563 Sec. 371 Date Aug. 30, 1994 Sec. 102(e) Date Aug. 30, 1994 PCT Filed Dec. 29, 1993 PCT Pub. No. WO94/16335 PCT Pub. Date Jul. 21, 1994.An arrangement for measuring the condition of a receiver antenna at a base station, utilizing an antenna amplifier positioned in connection with an antenna apart from other base station equipments, e.g., at a mast. A measuring signal is generated in connection with the other base station equipments at a frequency outside the frequency band used for radio traffic and applied through an antenna line to the antenna amplifier, in which the measuring signal is converted to the actual measuring frequency within the frequency band intended for the radio traffic.
Patent JP-2843442-B2 (JP)
IPC: A01N25/34
Filed: 1994-01-05
Granted: 1999-01-06
Abstract: PCT No. PCT/GB94/00010 Sec. 371 Date Jul. 5, 1995 Sec. 102(e) Date Jul. 5, 1995 PCT Filed Jan. 5, 1994 PCT Pub. No. WO94/15465 PCT Pub. Date Jul. 21, 1994An aqueous composition comprising a lower aliphatic peracid, a corrosion inhibitor and a peroxide stabilizer and/or peracid stabilizer, is useful for disinfecting medical equipment, particularly metal components of such equipment. A process for obtaining such compositions is also provided and comprises mixing a first aqueous solution comprising a lower aliphatic peracid with a second aqueous solution comprising hydrogen peroxide, a corrosion inhibitor and a hydrogen peroxide stabilizer and/or a peracid stabilizer. The first and second aqueous solutions can form a two pack system for obtaining such compositions.
Patent JP-2563888-B2 (JP)
IPC: G06F1/32
Filed: 1993-03-25
Granted: 1996-12-18
Abstract: Power dissipation of a CMOS circuit such as a microprocessor is reduced by dynamically slowing down the microprocessor clock during selected system operations such as hold, wait, or AT peripheral bus access cycles. The microprocessor clock is slowed to its minimum allowable frequency with precise synchronous control to maintain the accuracy of high frequency clock edges and to prevent glitches or substandard pulse widths.
Patent JP-4050312-B2 (JP)
IPC: A61K9/12
Filed: 1996-01-04
Granted: 2008-02-20
Abstract: The present invention for the first time discloses a health problem in broilers at about 3-5 weeks, resulting in significant production losses, and demonstrates that these production losses can be prevented by a live attenuated CAA vaccine for mucosal administration.
Patent JP-3704150-B2 (JP)
IPC: G02B21/08
Filed: 1995-02-08
Granted: 2005-10-05
Abstract: PCT No. PCT/DE95/00160 Sec. 371 Date Oct. 6, 1995 Sec. 102(e) Date Oct. 6, 1995 PCT Filed Feb. 8, 1995 PCT Pub. No. WO95/22072 PCT Pub. Date Aug. 17, 1995An exchangeable condenser system for a phase-contrast illuminating system (12) for microscopes has a plurality of different light rings (5), arranged on a nosepiece plate (4), assigned to the condenser optical system (6). The condenser optical system (6) can be exchanged independently of the light rings (5), the focal lengths Fn of the exchangeable condenser optical systems (6) being selected relative to one another in the ratio Fn=F0*Xn and the average diameters Dn of the light rings (5) being selected relative to one another in the ratio Dn=D0*Xn, where X>0, n=0,1,2,3, . . . .
Patent JP-2972344-B2 (JP)
IPC: C08G79/04
Filed: 1995-02-23
Granted: 1999-11-08
Abstract: Compounds are provided having the structure:   <IMAGE>   wherein the L groups are spanner or linker units, the Y and T group are functional groups for interacting with target molecules of interest, the X groups are oxygen or sulfur and the E groups are H, conjugate groups or intermediate groups used during the synthesis of the compounds are prepared using H phosphonate type chemistry wherein the functional groups are added during an oxidization step.
Patent JP-3472929-B2 (JP)
IPC: G01N33/569
Filed: 1996-02-21
Granted: 2003-12-02
Abstract: PCT No. PCT/GB96/00392 Sec. 371 Date Aug. 21, 1997 Sec. 102(e) Date Aug. 21, 1997 PCT Filed Feb. 21, 1996 PCT Pub. No. WO96/26443 PCT Pub. Date Aug. 29, 1996The present invention provides a method of detecting active antibody production in a blood sample by contacting, in the presence and absence of protein synthesis inhibitor, aliquots of the sample with a solid phase under conditions which permit antibody production and secretion by the lymphocytes; detecting in solution, binding of antibody to the antigen(s) on the solid phase; and comparing the antibody binding in the presence or absence of protein synthesis inhibitor, whereby to obtain a determination of the amount of active antibody secretion in response to the antigen(s); and kits for performing the method. The method may also be modified to allow detection of non-specific infection indicators.
Patent JP-3330613-B2 (JP)
IPC: C09C1/00
Filed: 1996-03-13
Granted: 2002-09-30
Abstract: A powder having metal oxide films on its surface is obtained in which the films have a heightened refractive index and which hence shows a high reflectance and has a bright color. A powder is obtained which has a reduced number of metal oxide films on the surface and hence has a small particle diameter. A powder having a multilayered film on the surface which comprises a base particle having on the surface thereof a multilayered film comprising at least a metal oxide film formed by the hydrolysis of a metal alkoxide, and in which the multilayered film has undergone a heat treatment. A process for producing any of the above powders which comprises dispersing a base particle into a solution of a metal alkoxide, hydrolyzing the metal alkoxide to obtain a metal oxide and deposit a film of the metal oxide on the surface of the base particle, conducting the foregoing steps two or more times to form a multilayered film, and performing a heat treatment in at least the final step, and in which the multilayered film is regulated so as to have an appropriate combination of constituent materials and appropriate film thicknesses to change the interference colors of the multilayered film and thus impart a bright color to the powder. <IMAGE>
Patent JP-3628710-B2 (JP)
IPC: A61F5/44
Filed: 1997-04-11
Granted: 2005-03-16
Abstract: The present invention pertains, in a preferred embodiment, to a stretchable, extensible, fluid-pervious composite web comprising an apertured, three-dimensional, macroscopically-expanded formed film layer and a fibrous layer, preferably a nonwoven, bonded to one side of the formed film layer. The composite web is microcreped in at least one direction, such that the composite web exhibits extensibility, and preferably also retractability, in that direction. The composite web exhibits fine scale nesting of the formed film layer and the nonwoven layer in the microfolds, providing intimate contact between the layers for enhanced fluid transport properties while the three-dimensionality of the formed film provides a stand-off between the layers. The composite webs of the present invention are particularly suited for use as a topsheet on an absorbent article, in order to provide for enhanced stretchability and extensibility to accommodate a wide range of in-use conditions and to enable the absorbent article to better conform to the wearer's body to improve wearing comfort via enhanced flexibility. The microcreped surface also provides a soft, pleasing visual and tactile impression to the wearer. The present invention further relates to a method of making a stretchable, extensible, fluid-pervious composite web comprising the steps of: (a) providing an apertured, three-dimensional, macroscopically-expanded formed film layer; (b) providing a fibrous layer; (c) bonding the fibrous layer to one side of the formed film layer to form a composite web; (d) microcreping the composite web in at least one direction such that the composite web is contracted that direction and such that the formed film layer remains substantially three-dimensional and macroscopically-expanded.
Patent ES-2319373-B2 (ES)
Title: Forjado ligero para pisos.
Inventor: FERNANDEZ CABO MIGUEL CARLOS
IPC: E04B5/12
Filed: 2008-08-06
Granted: 2010-04-05
Abstract: Forjado ligero para pisos, constituido a base de
módulo prefabricados en  forma de cajón abierto, realizado a base de
tableros OSB y listones de  madera conformando una estructura
autoportante. Los cajones se colocan  en forma de U invertida para
permitir tener un suelo de trabajo por la  parte superior. Entre la
rama de la U se dispone un panel de cierre que  limita una cámara
para el montaje de instalaciones de servicios.
Patent AU-2001270783-B2 (AU)
Title: Variolin derivatives as anti-cancer agents
Inventor: MANZANARES IGNACIO
IPC: C07D487/14
Filed: 2001-07-11
Granted: 2006-06-15
Abstract: The invention provides variolin derivatives of formula (I), wherein: R<SUB>1 </SUB>and R<SUB>2 </SUB>are each independently selected from the group consisting of H, OH, OR, SH, SR, SOR, SO<SUB>2</SUB>R, NO<SUB>2</SUB>, NH<SUB>2</SUB>, NHR, N(R)<SUB>2</SUB>, NHCOR, N(COR)<SUB>2</SUB>, NHSO<SUB>2</SUB>R, CN, halogen, C(-O)H, C(-O)R, CO<SUB>2</SUB>H, CO<SUB>2</SUB>R, C<SUB>1</SUB>-C<SUB>12 </SUB>alkyl, C<SUB>1</SUB>-C<SUB>12 </SUB>haloalkyl, C<SUB>2</SUB>-C<SUB>12 </SUB>alkenyl, C<SUB>2</SUB>-C<SUB>12 </SUB>alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted heteroaromatic; and R<SUB>3 </SUB>is selected from the group consisting of H, OH and OMe; wherein the or each group R is independently selected from the group consisting of OH, C<SUB>1</SUB>-C<SUB>12 </SUB>alkyl, C<SUB>1</SUB>-C<SUB>12 </SUB>haloalkyl, C<SUB>2</SUB>-C<SUB>12 </SUB>alkenyl, C<SUB>2</SUB>-C<SUB>12 </SUB>alkynyl, substituted or unsubstituted aryl, substituted unsubstituted aralkyl, substituted or unsubstituted arylalkenyl and substituted or unsubstituted heteroaromatic, and wherein the group R<SUB>1</SUB>, R<SUB>2 </SUB>or R<SUB>3 </SUB>is a group of formula N(R)<SUB>2 </SUB>or N(COR)<SUB>2</SUB>, each of the R groups may be the same or different, or the two R groups, together with the nitrogen atom to which they are attached, may form a 5-14 membered heterocyclic ring. These compounds display activity against a range of mammalian cancer cell lines. New synthetic routes to new and known variolin compounds, together with novel intermediates, are also disclosed. New antitumour activity of known variolin compounds is also described.
Patent AU-2001276515-B2 (AU)
Title: Suppressor gene
Inventor: LU XIN
IPC: A61K39/00
Filed: 2001-08-06
Granted: 2006-10-12
Abstract: The invention relates to the identification of a new member of a family of tumour suppressor genes (apoptosis stimulating proteins, ASP's) which encode polypeptides capable of modulating the activity of p53 and polypeptides capable of modulating the activity of said tumour suppressor polypeptide.
Patent AU-2001292758-B2 (AU)
Title: Method for heteroatom lattice substitution in large and extra-large pore borosilicate zeolites
Inventor: ZONES STACEY I
IPC: C01B39/00
Filed: 2001-09-12
Granted: 2007-01-11
Abstract: The present invention provides a method for preparing a zeolite having lattice substituted heteroatoms. The method includes: (a) contacting a calcined borosilicate zeolite with an acid, thereby producing an at least partially deboronated zeolite; and (b) contacting the at least partially deboronated zeolite with a salt-containing aqueous solution comprising one or more salts selected from the group consisting of aluminium salt, gallium salt, and iron salt, thereby producing a silicate or borosilicate zeolite having a lattice comprising aluminium atoms; gallium atoms, iron atoms or a combination thereof. Step (b) is conducted at a pH of about 3.5 or less. Preferably, step (a), step (b) or both are conducted at a temperature of from about ambient temperature to about 300°C, preferably, under stirring/tumbling.
Patent AU-2002216934-B2 (AU)
Title: Phase transfer of nanoparticles
Inventor: CARUSO FRANK
IPC: C09D11/00
Filed: 2001-11-23
Granted: 2004-07-08
Abstract: The invention relates to phase transfers of nanoparticles and to a catalysis using said nanoparticles. The aim of the invention is to facilitate a transfer of nanoparticles from an organic solution to an inorganic, especially, aqueous solution. To this end, a generically describable substance class, for example the commercially available 4-dimethylaminopyridine (DMAP), which is for example dissolved in water, is added to the organic solution in sufficient amounts. This measure has the effect that the nanoparticles are readily transferred in a one-step process from the organic phase (in each case in the top section) to the inorganic phase (in each case in the lower section) in the sample container.
Patent AU-2002242115-B2 (AU)
Title: Dual input AC and DC power supply having a programmable DC output utilizing a secondary buck converter
Inventor: SMITH SCOTT
IPC: H02J9/06
Filed: 2002-02-08
Granted: 2006-09-14
Abstract: A power converter capable of receiving either an AC input voltage or a DC input voltage and generating a programmable DC output voltage. The converter comprises a first circuit that converts an AC input voltage to a predetermined DC first output voltage, and a second circuit that converts a DC input voltage to a predetermined second DC output voltage. The converter also comprise a third circuit which is adapted to receive the first and second DC voltages from first and second circuits to generate a selectable output DC voltage. In selected embodiments, the first and second DC output voltages provided by the first and second circuits, respectively, are generally the same value and are coupled to a common node that feeds the input terminal of the third circuit. Moreover, the third circuit is adapted to provide a selectable output DC voltage which may be set higher or lower than its DC input voltage. The third circuit may also be adapted to couple a set of removable programming keys that provide for a different associated DC output voltage. The programming key comprises a resistor, which may provide for a variety of functions, such as current-limiting, over-voltage protection, output voltage programming, and wrong-tip circuit protection.
Patent AU-2002327065-B2 (AU)
Title: Suturing apparatus and method
Inventor: BANNERMAN BRETT
IPC: A61B17/06
Filed: 2002-09-25
Granted: 2007-12-20
Abstract: A suturing apparatus (10) comprises a pair of jaws. A bendable needle (32) housed in one of the jaws is adapted to carry a suture (34). A suture receiver (41) is disposed adjacent to the opposite jaw. A transition block curves the needle and directs it in a direction generally unparallel to an axis of the carrying jaw. The needle may also be configured to retrieve a suture. A retaining mechanism holds a suture in place to be engaged by the needle. The jaw housing the needle may include a lateral opening through which the suture may be inserted. The needle may also include a lateral notch which may be aligned with lateral opening to receive the suture. An actuator coupled to the needle enables the user to move the needle proximally to align the notch with the lateral slot.
Patent AU-2002338531-B2 (AU)
Title: Clamp having bendable shaft
Inventor: BUELNA TERRENCE J
IPC: A61B17/122
Filed: 2002-05-01
Granted: 2005-12-22
Abstract: A shaft assembly that has a flexible shaft and a series of alternating rigid beads around the flexible shaft that ensure the shaft is kept rigid while in any position when the shaft is locked. The flexible shaft having a proximal end that is operatively coupled to the handle assembly and a distal end that operatively coupled to the gripping assembly. The shaft assembly also has a rigid element that can be placed in a first position where the rigid element supports the shaft in a manner where the shaft cannot be bent, and in a second position where the shaft can be bent. The series of alternating beads is made up of an alternating series of 2 types of beads.